Evidence map›Paper›PMID 41588163›Full record

ArticleNature microbiology2026

Effector-host interactome map links type III secretion systems in healthy gut microbiomes to immune modulation.

Veronika Young, Bushra Dohai, Hridi Halder, Jaime Fernandez-Macgregor, Niels S van Heusden, Thomas C A Hitch, Benjamin Weller, Patrick Hyden, Deeya Saha, Daan K J Pieren and 33 more

Abstract read
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Commensals join the effector game.Nature immunology · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Veronika Young *Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-1524-8039
Bushra Dohai *Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Hridi HalderInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Jaime Fernandez-MacgregorAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.
Niels S van HeusdenCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0002-8346-1990
Thomas C A HitchFunctional Microbiome Research Group, Institute of Medical Microbiology, University Hospital of RWTH Aachen, Aachen, Germany.ORCID http://orcid.org/0000-0003-2244-7412
Benjamin WellerInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Patrick HydenDepartment of Microbiology and Ecosystem Science, Research Network: Chemistry meets Microbiology, University of Vienna, Vienna, Austria.
Deeya SahaAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.
Daan K J PierenCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-0461-5064
Sonja RittchenCenter for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Luke LambourneCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7001-7575
Sibusiso B MasekoLaboratory of Viral Interactomes, GIGA Institute, University of Liège, Liège, Belgium.
Chung-Wen LinInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Ye Min TunInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Jonas BibusDr von Hauner Children's Hospital, Department of Pediatrics, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Luisa PletschacherInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Mégane BoujeantAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.
Sébastien A ChoteauAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.
Lou BergogneAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.ORCID http://orcid.org/0009-0004-9409-0154
Jérémie PerrinAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.
Franziska OberResearch Unit Signaling and Translation, Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Patrick SchwehnInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Simin T RothballerInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Melina AltmannInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Stefan AltmannInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Alexandra StrobelInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Michael RothballerInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Marie TofauteResearch Unit Signaling and Translation, Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Daniel KotlarzDr von Hauner Children's Hospital, Department of Pediatrics, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Matthias HeinigInstitute of Computational Biology (ICB), Computational Health Center, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Thomas ClavelFunctional Microbiome Research Group, Institute of Medical Microbiology, University Hospital of RWTH Aachen, Aachen, Germany.ORCID http://orcid.org/0000-0002-7229-5595
Michael A CalderwoodCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6475-1418
Marc VidalCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
Jean-Claude TwizereLaboratory of Viral Interactomes, GIGA Institute, University of Liège, Liège, Belgium.ORCID http://orcid.org/0000-0002-8683-705X
Renaud VincentelliAix-Marseille University, CNRS, AFMB, UMR CNRS 7257, Turing Center for Living Systems, Marseille, France.ORCID http://orcid.org/0000-0001-9667-0196
Daniel KrappmannResearch Unit Signaling and Translation, Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.ORCID http://orcid.org/0000-0001-7640-3234
Marianne BoesCenter for Translational Immunology, Pediatrics Department, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-2590-1692
Claudia FalterInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Thomas RatteiDepartment of Microbiology and Ecosystem Science, Research Network: Chemistry meets Microbiology, University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-0592-7791
Christine BrunAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France.
Andreas ZanzoniAix-Marseille University, INSERM, TAGC, UMR_S1090, Turing Center for Living Systems, Marseille, France. andreas.zanzoni@univ-amu.fr.ORCID http://orcid.org/0000-0002-4818-6161
Pascal Falter-BraunInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany. pascal.falter-braun@helmholtz-munich.de.ORCID http://orcid.org/0000-0003-2012-6746

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-16-CONV-0001Agence Nationale de la Recherche (French National Research Agency) ANR-17-HDIM-000Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01EA1803Deutsche Forschungsgemeinschaft (German Research Foundation) 210592381Deutsche Forschungsgemeinschaft (German Research Foundation) 403224013EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101003633Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 11819559
6 · The paper itself

Abstract

Pseudomonadota (formerly Proteobacteria) are prevalent in the commensal human gut microbiota, but also include many pathogens that rely on secretion systems to support pathogenicity by injecting proteins into host cells. Here we show that 80% of Pseudomonadota from healthy gut microbiomes also have intact type III secretion systems (T3SS). Candidate effectors predicted by machine learning display sequence and structural features that are distinct from those of pathogen effectors. Towards a systems-level functional understanding, we experimentally constructed a protein-protein meta-interactome map between human proteins and commensal effectors. Network analyses uncovered that effector-targeted neighbourhoods are enriched for genetic variation linked to microbiome-associated conditions, including autoimmune and metabolic diseases. Metagenomic analysis revealed effector enrichment in Crohn's disease but depletion in ulcerative colitis. Functionally, commensal effectors can translocate into human cells and modulate NF-κB signalling and cytokine secretion in vitro. Our findings indicate that T3SS contribute to microorganism-host cohabitation and that effector-host protein interactions may represent an underappreciated route by which commensal gut microbiota influences health.

Indexed as

Gastrointestinal MicrobiomeImmunomodulationType III Secretion SystemsBacterial ProteinsColitis, UlcerativeCrohn DiseaseHost Microbial InteractionsHost-Pathogen InteractionsHumansMetagenomicsNF-kappa BProtein Interaction MapsBacterial ProteinsNF-kappa BType III Secretion Systems

Identifiers

PMID41588163
PMCPMC12872453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.